Figure 3.
Effect of prognostic features on the clinical course of CLL. Rate of disease progression as assessed by the treatment-free time interval measured in months from diagnosis for (A) ZAP-70 mRNA expression, (B) IgVH mutation status, (C) CD38 protein expression with cutoff of 7%, and (D) CD38 protein expression with cutoff of 30%.